DK0440147T3 - Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker") - Google Patents

Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker")

Info

Publication number
DK0440147T3
DK0440147T3 DK91101095T DK91101095T DK0440147T3 DK 0440147 T3 DK0440147 T3 DK 0440147T3 DK 91101095 T DK91101095 T DK 91101095T DK 91101095 T DK91101095 T DK 91101095T DK 0440147 T3 DK0440147 T3 DK 0440147T3
Authority
DK
Denmark
Prior art keywords
human antibody
preparation
human
cdna
gene banks
Prior art date
Application number
DK91101095T
Other languages
English (en)
Inventor
Melvyn Dr Little
Thomas Dr Seehaus
Stefan Duebel
Frank Berthold Breitling
Iris Klewinghaus
Original Assignee
Dade Behring Marburg Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25889602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0440147(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4002898A external-priority patent/DE4002898A1/de
Priority claimed from DE4003881A external-priority patent/DE4003881A1/de
Application filed by Dade Behring Marburg Gmbh filed Critical Dade Behring Marburg Gmbh
Application granted granted Critical
Publication of DK0440147T3 publication Critical patent/DK0440147T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/6857—Antibody fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91101095T 1990-02-01 1991-01-28 Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker") DK0440147T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4002898A DE4002898A1 (de) 1990-02-01 1990-02-01 Herstellung und verwendung von genbanken menschlicher antikoerper ("human-antikoerper-bibliotheken")
DE4003881A DE4003881A1 (de) 1990-02-09 1990-02-09 Herstellung und verwendung von genbanken menschlicher antikoerper ("human-antikoerper-bibliotheken")

Publications (1)

Publication Number Publication Date
DK0440147T3 true DK0440147T3 (da) 2005-01-17

Family

ID=25889602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91101095T DK0440147T3 (da) 1990-02-01 1991-01-28 Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker")

Country Status (12)

Country Link
US (1) US6319690B1 (da)
EP (2) EP0440147B2 (da)
JP (1) JP3514778B2 (da)
KR (1) KR100186823B1 (da)
AT (2) ATE277179T1 (da)
AU (1) AU633682B2 (da)
CA (1) CA2035381C (da)
DE (2) DE59109273D1 (da)
DK (1) DK0440147T3 (da)
ES (2) ES2336444T3 (da)
IE (1) IE910335A1 (da)
PT (1) PT96625B (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE59109273D1 (de) † 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")
JP3502093B2 (ja) * 1991-07-15 2004-03-02 ザ・ウエルカム・ファウンデーション・リミテッド 抗体の製造
DE4142077A1 (de) * 1991-12-19 1993-06-24 Boehringer Mannheim Gmbh Verfahren zur expression rekombinanter antikoerper
EP1231268B1 (en) * 1994-01-31 2005-07-27 Trustees Of Boston University Polyclonal antibody libraries
DE19728697C1 (de) * 1997-07-04 1999-03-25 Deutsches Krebsforsch Humaner Antikörper gegen ein Fusions(poly)peptid bzw. -protein, das einen Anteil von mindestens sechs Histidinen aufweist
AU9148498A (en) * 1997-09-19 1999-04-12 Medleys Laboratories Inc. Method and kit for early diagnosis of autoimmunity and lymphoma in central nervous system
US7270969B2 (en) * 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
DK2230303T3 (da) * 1999-05-05 2013-04-15 Phylogica Ltd Isolering af biologiske modulatorer fra biodiverse genfragment-biblioteker
US7803765B2 (en) * 1999-05-05 2010-09-28 Phylogica Limited Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefrom
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
PT2308982E (pt) * 2000-04-17 2015-03-04 Dyax Corp Métodos para construir bibliotecas de pacotes genéticos que representam os membros de uma família diversificada de péptidos
ES2430857T3 (es) 2000-12-18 2013-11-22 Dyax Corp. Bibliotecas focalizadas de paquetes genéticos
WO2003035842A2 (en) * 2001-10-24 2003-05-01 Dyax Corporation Hybridization control of sequence variation
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
AU2005207003C1 (en) 2004-01-20 2013-06-13 Humanigen, Inc. Antibody specificity transfer using minimal essential binding determinants
WO2005087812A1 (en) * 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for vegf/pdgf family of growth factors
EP1754052B1 (en) * 2004-06-03 2015-07-22 Phylogica Limited Peptide modulators of cellular phenotype and bi-nucleic acid fragment library
EA019505B1 (ru) * 2005-12-16 2014-04-30 Рибовакс Байотекнолоджиз Са Способ получения иммортализованных клеток, секретирующих антитела, популяция иммортализованных клеток и ее применения
DK1973946T3 (da) 2006-01-20 2015-06-22 Cell Signaling Technology Inc Translokation og mutant ros kinase i human ikke-småcellet lungekarcinom
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
JP5576610B2 (ja) 2006-02-20 2014-08-20 フィロジカ リミテッド ペプチド構造のライブラリーの構築およびスクリーニング方法
US7700339B2 (en) 2006-04-14 2010-04-20 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2074138A4 (en) * 2006-09-19 2009-12-30 Phylogica Ltd NEUROPROTECTIVE PEPTIDE AP-1 SIGNALING INHIBITORS AND USES THEREOF
WO2008154700A1 (en) * 2007-06-20 2008-12-24 Phylogica Limited Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ards) and clinical disorders associated with therewith
CA3187687A1 (en) * 2007-09-14 2009-03-19 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3072963B1 (en) 2007-10-18 2020-04-01 Cell Signaling Technology, Inc. Translocation and mutant ros kinase in human non-small cell lung carcinoma
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
DK2281078T3 (da) * 2008-04-24 2015-02-02 Dyax Corp Biblioteker af genpakker, der omfatter hidtil ukendte hc-cdr1, -cdr2 og -cdr3 og hidtil ukendte lc-cdr1-, -cdr2- og -cdr3-designs
DK2881402T3 (da) 2009-02-12 2017-08-28 Cell Signaling Technology Inc Mutant ROS-ekspression i human levercancer
CA2773564A1 (en) * 2009-09-14 2011-03-17 Dyax Corp. Libraries of genetic packages comprising novel hc cdr3 designs
WO2011084605A1 (en) * 2009-12-16 2011-07-14 The Trustees Of The University Of Pennsylvania Anti-prostate cancer antibodies and methods of detection and treatment of prostate cancer using the same
EP3336225B1 (en) * 2010-07-16 2020-02-19 Adimab, LLC Antibody libraries
WO2012019132A2 (en) 2010-08-06 2012-02-09 Cell Signaling Technology, Inc. Anaplastic lymphoma kinase in kidney cancer
CN103619877B (zh) 2011-04-21 2018-01-02 加文医学研究所 修饰的可变结构域分子及其产生和使用方法b
DK2838998T3 (da) 2012-04-18 2018-01-15 Cell Signaling Technology Inc Egfr og ros1 i kræft
ES2796259T3 (es) * 2014-05-29 2020-11-26 Siemens Healthcare Diagnostics Inc Detección de moléculas raras
IL322943A (en) 2017-07-11 2025-10-01 Compass Therapeutics Llc Agonist antibodies that bind human CD137 and their use
US11718679B2 (en) 2017-10-31 2023-08-08 Compass Therapeutics Llc CD137 antibodies and PD-1 antagonists and uses thereof
EP3713961A2 (en) 2017-11-20 2020-09-30 Compass Therapeutics LLC Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
US11046769B2 (en) 2018-11-13 2021-06-29 Compass Therapeutics Llc Multispecific binding constructs against checkpoint molecules and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE102631T1 (de) * 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
CA2016842A1 (en) * 1989-05-16 1990-11-16 Richard A. Lerner Method for tapping the immunological repertoire
CA2016841C (en) † 1989-05-16 1999-09-21 William D. Huse A method for producing polymers having a preselected activity
WO1991010737A1 (en) * 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
DE59109273D1 (de) † 1990-02-01 2010-01-07 Siemens Healthcare Diagnostics Herstellung und Verwendung von Genbanken menschlicher Antikörper("Human-Antikörper-Bibliotheken")

Also Published As

Publication number Publication date
EP0440147B2 (de) 2014-05-14
EP1566442A2 (de) 2005-08-24
ES2336444T3 (es) 2010-04-13
ES2225816T3 (es) 2005-03-16
JPH04211394A (ja) 1992-08-03
PT96625B (pt) 1998-07-31
ATE449853T1 (de) 2009-12-15
JP3514778B2 (ja) 2004-03-31
US6319690B1 (en) 2001-11-20
CA2035381C (en) 2004-11-09
EP0440147A3 (en) 1992-07-08
IE910335A1 (en) 1991-08-14
PT96625A (pt) 1991-11-29
CA2035381A1 (en) 1991-08-02
ATE277179T1 (de) 2004-10-15
KR100186823B1 (ko) 1999-04-01
AU633682B2 (en) 1993-02-04
DE59109264D1 (de) 2004-10-28
KR910021475A (ko) 1991-12-20
AU7011391A (en) 1991-08-08
EP1566442B1 (de) 2009-11-25
EP0440147A2 (de) 1991-08-07
EP1566442A3 (de) 2006-06-07
EP0440147B1 (de) 2004-09-22
DE59109273D1 (de) 2010-01-07
ES2225816T5 (es) 2014-08-21

Similar Documents

Publication Publication Date Title
DK0440147T3 (da) Fremstilling og anvendelse af genbanker af humant antistof ("humant-antistof-biblioteker")
Bank et al. A functional T3 molecule associated with a novel heterodimer on the surface of immature human thymocytes
Lohmann-Matthes et al. Promonocytes have the functional characteristics of natural killer cells
Penman et al. Polyribosomes in normal and poliovirus-infected HeLa cells and their relationship to messenger-RNA
US5780225A (en) Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
Fujitani et al. Transcriptional activation of the IL-6 response element in the junB promoter is mediated by multiple Stat family proteins
CA2348954A1 (en) A pharmaceutical composition for treating immune diseases
CA2035384A1 (en) Preparation and use of gene banks of synthetic human antibodies ("synthetic human-antibody libraries")
Kaufmann et al. Mechanism of action of Cyclosporin A: inhibition of lymphokine secretion studied with antigen-stimulated T cell hybridomas.
WO1997002479A2 (en) Human monoclonal anti-tumor antibodies
CA2344086A1 (en) Human monoclonal antibody against a costimulatory signal transduction molecule ailim and pharmaceutical use thereof
MX9709778A (es) Anticuerpos monoclonales humanos de alta afinidad especificos para la proteina f del virus sincitial respiratorio.
Palmer et al. Selection of antibodies to cell surface determinants on mouse thymic epithelial cells using a phage display library
DE69328376D1 (de) Feststellung der cystic fibrosis oder einer mutation des cftr gens
Hasegawa et al. Are Ly1 B cells responsible for the IL2-hyperresponsiveness of B cells in autoimmune-prone NZB× NZW F1 mice?
DE69533504D1 (de) Monoklonale antikörper gegen antigene, die durch hämatopoietische helferzellen exprimiert werden
Ishida et al. Unique cell surface phenotypes of proliferating lymphocytes in mice homozygous for lpr and gld mutations, defined by monoclonal antibodies to MRL/Mp-lpr/lpr T cells
Saitovitch et al. Induction of transplantation tolerance using a nondepleting anti-CD4 MAb and donor-specific transfusion before transplantation: evidence that a critical period of time is required for the development of immunological unresponsiveness
Schröder et al. Specificity of monoclonal antibodies to an EBV transformed B-cell line
ATE56617T1 (de) Anti-urokinase monoklonaler antikoerper, seine herstellung und verwendung.
Yang et al. Differential expression of novel genes by bone marrow-derived macrophage populations
Noll et al. Production and characterization of four monoclonal antibodies specific for human interferon-alpha-1 and-alpha-2
Leclercq et al. Direct Evidence for Partial Target Specificity in Lymphokine‐Activated Killer Thymocytes
RU94026276A (ru) Рецепторы интерлейкина-12 и антител
Specter et al. Immunosuppressive factors produced by tumors and their effects on the RES